Imatinib mesylate inhibits CD4(+)CD25(+) regulatory T cell activity and enhances active immunotherapy against BCR-ABL(negative) tumors

Imatinib mesylate (Gleevec, STI571), a selective inhibitor of a restricted number of tyrosine kinases, has been effectively used for the treatment of Philadelphia chromosome positive leukemias and gastrointestinal stromal tumors. Imatinib may also directly influence immune cells. Suppressive as well...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Larmonier, Nicolas, Janikashvili, Nona, LaCasse, Collin J., Larmonier, Claire B., Cantrell, Jessica, Situ, Elaine, Lundeen, Tamara, Bonnotte, Bernard, Katsanis, Emmanuel
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2008
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2579962/
https://ncbi.nlm.nih.gov/pubmed/18981115
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge